Tirzepatide
Indication
Managing overweight and obesity in primary care
Black
Brand:
Mounjaro
Nice TA:
1026
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Mounjaro® (Tirzepatide) has been reviewed by NICE for managing overweight and obesity (NICE TA1026) and will be made available to NHS patients according to the following stages:
1. Available by spring 2025 to all patients accessing specialist weight management services, and
2. Available by summer 2025 for a phased introduction of delivery to eligible cohorts, in line with NHS England’s interim commissioning policy, in primary care.
LSCMMG has agreed that the RAG status of tirzepatide for the management of overweight and obesity will reflect the availability of tirzepatide as defined by NICE and NHS England.
It is expected that the RAG position will be updated periodically and in line with the implementation plan.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: